Featured Content

Thomas Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

Cancer Doctors Plan to Compare Value of Expensive Drugs

(Bloomberg) Apr 17, 2014 - The world’s largest organization of cancer doctors plans to rate the cost effectiveness of expensive oncology drugs, and will urge physicians to use the ratings to discuss the costs with their patients.

Commentary: The cost of drug is an issue we have been dealing with forever. No question however that as the price of new drugs...

OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

GSK and Genmab Receive FDA Approval for Arzerra (ofatumumab) as First-Line Treatment in Combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia (CLL) for Whom Fludarabine-Based Therapy Is Considered Inappropriate

(Morningstar) Apr 17, 2014 - Arzerra now approved for use in previously untreated patients for whom fludarabine-based therapy is considered inappropriate; approval based on Phase III data from study with ofatumumab + chlorambucil.
read article »

FDA Warns Against Procedure to Remove Uterine Fibroids; Says It Could Spread Hidden Cancer

(Washington Post) Apr 17, 2014 - The Food and Drug Administration on Thursday took the rare step of urging doctors to stop performing a surgical procedure used on tens of thousands of women each year to remove uterine growths, saying the practice risks spreading hidden cancers within a woman’s body.
read article (free registration required) »


View ALL News »

News Story Commentary By Academic and Community Oncologists

Cancer Doctors Plan to Compare Value of Expensive Drugs (Bloomberg)

The cost of drug is an issue we have been dealing with forever. No question however that as the price of new drugs...posted by: Thomas Marsland, MD

New Kind of Trial Aims to Speed Cancer Drug Development (Reuters)

I applaud the efforts of ASCO to come up with novel ways of measuring the value of new oncology drugs based on...posted by: William Harwin MD

Gene Panel Effectively Screens Dozens of Genes for Cancer-associated Mutations, Study Finds (Stanford School of Medicine)

Given the constant evolving world of genomic testing and molecular profiling, this is definitely an area that payers...posted by: Winston Wong, PharmD

FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon? (TheStreet)

Aside from the embarrassing error, I think that as relevant an issue is the fact that this was sent out by Inspire...posted by: H. Jack, West, MD

Medicare Considers Using NCCN Guides as Clinical Pathways (Medscape Medical News)

I have to wonder if CMS's application of the NCCN guidelines will have much impact at all. Where my comment comes...posted by: Winston, Wong, PharmD

OBR Training

Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.

OBR Job Board

Novocure has posted 6 new jobs.

View OBR Job Board>>

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™

View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.


Symbol  %Δ
GALT +12.94%
PVCT +9.95%
SRNE +9.33%
INO -5.62%
THLD -4.73%
INFI -4.25%


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results

Date: April 19, 2014
Company: GlaxoSmithKline and Genmab A/S
Product: Arzerra® (ofatumumab)

Date: June 16, 2014
Company: Navidea Biopharmaceuticals
Product: Lymphoseek® (technetium Tc 99m tilmanocept) Injection

Date: June 23, 2014
Company: Eli Lilly & Co.
Product: Ramucirumab (IMC-1121B)

See All OBR Radar items»